Southwest Research Institute

Medical

biotech, biotechnology, cell, gene, tissue | June 10, 2022

SOPHiA GENETICS (Nasdaq: SOPH), the Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) of Barcelona, and the Spanish Diagnóstica Longwood today announced from the European Hematology Association Congress in Vienna that they have combined their expertise to develop a new Chronic Lymphocytic Leukemia (CLL) solution to advance CLL care. This collaboration will unify the wide variety of current guideline recommendations into one single application aiming to improve ...

Cell and Gene Therapy

Spotlight Therapeutics | December 01, 2020

Spotlight Therapeutics, Inc., a biotechnology organization creating non-viral quality altering therapeutics for direct in vivo altering of target genes, closed its Series A financing bringing the complete raised to $30 million. The financing was driven by GV, in the past Google Ventures, with interest from extra undisclosed investors. Realizing the full revolutionary potential of CRISPR genome editing requires the ability to edit target genes directly in the right cells of the hum...

Cell and Gene Therapy

BeiGene | November 23, 2021

BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines, announced that the first patient has been dosed in a Phase 1 clinical trial of BGB-23339, a potent, allosteric investigational tyrosine kinase 2 (TYK2) inhibitor internally developed by BeiGene scientists. TYK2 is a member of the JAK family and functions as a critical mediator in cytokine signaling pathways implicated in multiple immune-mediated disorders, such as psor...

Maravai LifeSciences | April 27, 2020

TriLink BioTechnologies®, a Maravai LifeSciences company and a leader in the production of nucleic acids for research, diagnostics and therapeutics applications, and Imperial College London, a public research university located in the United Kingdom, announced today that they have entered into a partnership in which TriLink will manufacture self-amplifying RNA (saRNA) for COVID-19 vaccine development. The vaccine development program is led by Professor Robin Shattock, Head of Mucosal Infecti...